A phase III trial of arhalofenate in combination with febuxostat in patients with chronic gout
Phase of Trial: Phase III
Latest Information Update: 20 Jan 2016
At a glance
- Drugs Arhalofenate (Primary) ; Febuxostat
- Indications Gout
- Focus Registrational; Therapeutic Use
- Sponsors CymaBay Therapeutics
- 20 Jan 2016 According to a CymaBay Therapeutics media release, this is one of the 3 trials that will support registration.
- 12 Nov 2015 According to a CymaBay Therapeutics media release,the company held a positive End-of-Phase 2 meeting with the FDA in September 2015, and an agreement was reached on the primary endpoint and target patient number.
- 02 Mar 2015 New trial record